Ocumension Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	543.72	417.31	246.37	158.96	56.15	13.1
Revenue Growth (YoY)	75.23%	69.38%	54.99%	183.11%	328.73%	6792.63%
Cost of Revenue	312.21	192.24	102	56.04	19.21	1.72
Gross Profit	231.51	225.07	144.37	102.92	36.94	11.37
Selling, General & Admin	417.49	416.91	422.4	373.79	253.81	283.54
Research & Development	94.22	113.94	123.77	184.31	169.06	179.55
Operating Expenses	512.07	531.5	546.51	558.78	422.86	463.09
Operating Income	-280.56	-306.43	-402.15	-455.86	-385.93	-451.72
Interest Expense	-1.16	-2.16	-1.33	-1.79	-0.57	-0.06
Interest & Investment Income	11.97	22.22	21.92	28.22	26.89	14.25
Earnings From Equity Investments	-	-	-	-	-13.33	-
Currency Exchange Gain (Loss)	-0.77	1.92	1.1	22.42	-13.37	-102.57
Other Non Operating Income (Expenses)	20.56	16.91	-3.36	7.31	0.54	-37.86
EBT Excluding Unusual Items	-249.95	-267.55	-383.81	-399.71	-385.77	-577.95
Gain (Loss) on Sale of Investments	1.75	0.29	1.16	1.25	99.84	7.63
Asset Writedown	-	-	3.18	-3.18	-	-
Other Unusual Items	-	-	-	-0.6	25.94	-1,695
Pretax Income	-248.21	-267.26	-379.48	-402.23	-259.99	-2,265
Income Tax Expense	1.04	1.02	0.31	0.41	-	-
Earnings From Continuing Operations	-249.25	-268.27	-379.79	-402.64	-259.99	-2,265
Net Income	-249.25	-268.27	-379.79	-402.64	-259.99	-2,265
Net Income to Common	-249.25	-268.27	-379.79	-402.64	-259.99	-2,265
Shares Outstanding (Basic)	749	684	649	633	607	302
Shares Outstanding (Diluted)	749	684	649	633	607	302
Shares Change (YoY)	14.21%	5.33%	2.63%	4.18%	100.81%	637.00%
EPS (Basic)	-0.33	-0.39	-0.59	-0.64	-0.43	-7.49
EPS (Diluted)	-0.33	-0.39	-0.59	-0.64	-0.43	-7.49
Free Cash Flow	-195.07	-225.92	-258.84	-316.47	-392.22	-262.74
Free Cash Flow Per Share	-0.26	-0.33	-0.40	-0.50	-0.65	-0.87
Gross Margin	42.58%	53.93%	58.60%	64.74%	65.78%	86.84%
Operating Margin	-51.60%	-73.43%	-163.23%	-286.78%	-687.36%	-3449.28%
Profit Margin	-45.84%	-64.29%	-154.16%	-253.30%	-463.06%	-17294.33%
Free Cash Flow Margin	-35.88%	-54.14%	-105.06%	-199.09%	-698.57%	-2006.27%
EBITDA	-168.2	-229.36	-355.76	-428.76	-376.31	-448.62
EBITDA Margin	-30.94%	-54.96%	-144.40%	-269.74%	-	-
D&A For EBITDA	112.36	77.07	46.39	27.1	9.62	3.1
EBIT	-280.56	-306.43	-402.15	-455.86	-385.93	-451.72
EBIT Margin	-51.60%	-73.43%	-163.23%	-286.78%	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.